Cipla and Stempeutics Research collaborate for Stempeucel launch

Cipla Limited announced on Thursday that its partner, Stempeutics Research Pvt Ltd has received regulatory approval by Drug Controller General of India (DCGI) for the launch of Stempeucel® in India.

The product is indicated for the treatment of critical limb ischemia (CLI), caused due to Buerger’s disease and Atherosclerotic peripheral arterial disease. Buerger's disease affects blood vessels in the body, usually in the arms and legs. Blood vessels swell, which prevents blood flow and results in clot formation.

Peripheral artery disease (PAD) is a disease of the blood vessels located outside the heart and brain. They are most often caused by a buildup of fatty deposits in the arteries. The most common cause of PAD is atherosclerosis. Atherosclerosis is a gradual process of a fatty material building up inside the arteries.

It is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment. Allogeneic Cell therapies rely on a single source of cells to treat many patients.

The product has been developed by Stempeutics over a period of twelve years. Under the agreement signed between the two companies, Cipla has received exclusive rights to market and distribute the product in India by leveraging its expansive distribution strengths across the country.

The stock closed at 762.65, up by 0.55 per cent or Rs 4.20 per share. The intraday high is Rs 771.60 and the intraday low is Rs 758.45.